News

U.S. FDA has assigned a target action date of January 28, 2022. Application based on results from the Phase 3 EXPLORER-HCM trial Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug...

The trial aims to demonstrate the safety and efficiency of a leadless II pacemaker system in patients with abnormal heart rhythm HonorHealth, a leading community healthcare system serving 1.6 million people in the greater Phoenix area, and...

Applications open now for May 12 first round pitch event Congenital heart disease (CHD) affects six out of 1,000 babies born in the U.S. each year and is often complicated by arrhythmias, a condition where the heart beats too rapidly, too...

Milestone achieved as company prepares for next stage of commercial growth and expansion  Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure, announced the 100th global...

A clinical study of a new cardiac ablation procedure for patients with an irregular heartbeat has launched at Beaumont Health, a worldwide leader in the treatment of atrial fibrillation, or AFib. Researchers at Beaumont Hospital, Royal Oak...

CathVision ApS, a medical device company developing a novel artificial intelligence therapeutic platform for cardiac electrophysiology procedures, is announcing a change to its Board of Directors. Meghna Eichelberger, Partner and Associate...

PaceMate™ announces its recent listing with premier electronic health record company Epic.

Horizon Technology Finance Corporation, a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and...

AliveCor, the global leader in FDA-cleared personal electrocardiogram (ECG) technology and services, announced the appointment of Clyde Hosein as its Chief Financial Officer. Hosein brings more than 30 years of leadership experience in...